Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging). Twittorial below Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)... 1/n

🩻Contrast-induced AKI: one of the biggest myths still shaping clinical decisions For decades we were taught: 👉 “Contrast damages the kidneys” 👉 “Avoid CT with contrast in CKD” 👉 “Hydrate, protect, delay imaging if needed” But what if… most of this is wrong?🤔 ->The uncomfortable reality Modern evidence shows: 👉 Low-osmolar contrast rarely causes true nephrotoxicity 👉 Even in CKD, AKI, and ICU patients 👉 The risk is often overestimated—or nonexistent So where did the fear come from? 📍 1950s high-osmolar contrast (actually toxic) 📍 Poorly controlled observational studies 📍 “Creatinine rise = contrast injury” assumption 👉 Correlation became causation 👉 And the dogma stayed ⚠️What recent data tells us ✔ No difference in AKI rates with vs without contrast ✔ No benefit from bicarbonate, NAC, or aggressive hydration ✔ Even ICU and AKI patients show no worsening outcomes ->Translation to real life 👉 The patient was going to develop AKI anyway...Not because of contrast!! ->The real problem: “Renalism” 👉 Avoiding necessary imaging 👉 Delaying diagnosis 👉 Choosing inferior tests And that leads to: ❌ Missed PE ❌ Delayed sepsis source control ❌ Worse outcomes ->Clinical mindset shift Instead of asking: 👉 “Will contrast harm the kidneys?” We should ask: 👉 “Will NOT doing the scan harm the patient?” ->Who still deserves caution? ✔ eGFR <30 ✔ Severe hemodynamic instability ✔ Multiple nephrotoxins Even then: 👉 Optimize volume 👉 Minimize dose 👉 Don’t delay critical imaging 🤓Bottom line ✔ Contrast nephrotoxicity exists… but is rare ✔ The fear is bigger than the risk ✔ The harm of NOT imaging is often greater In critical care 👉 We don’t treat creatinine 👉 We treat patients And sometimes… 👉 The most dangerous thing is NOT the contrast 👉 It’s hesitation. 📃Reference Florens N, Demiselle J. Kidney360 7: 445–449, 2026. doi: doi.org/10.34067/KID.0000001…

Prof Hugosson: Göteborg trial with 30 year outcomes! NND falls to -6-, with greatest benefit for men 50-59 at randomization. Despite no image guidance, high overdx, and suboptimal tx. Best evidence we have re: the evidence for #prostatecancer screening. Get tested! #eau26 @uroweb

#EAU26 @ChrisSweens1: the field is reaching a consensus in mHSPC. ADT ARPI for nearly all patients, then personalize intensification: • SBRT for low-volume • Prostate RT in synchronous disease • Docetaxel if high-volume and chemofit 🕒 The hope for the future: biomarkers to guide therapy, global access, and drug prices coming down so evidence-based care becomes feasible worldwide. @uroweb @UroToday

Thanks for the shoutout Tom. We need to help our patients and deliver a unified message: The OS advantage seen with EV P relies on consolidation with Radical Cystectomy PLND (not observation, not TMT) #EAU26

"Who needs surgery after neoadj chemo" plenary by Dr. Zlotta #EAU26 - pCR now >50% w/ EV P regardless of cis-eligibility - Predicting pT0 remains a challenge - Future of MIBC tx will need multi-modal, risk-adapted approach (🔊 NEO-BLAST trial led by @MariePierStLau1 @pcvblack)

Meta-analysis in HR-NMIBC: intraves Gem/Doce showed 24-mo RFS of 78% (BCG-naïve) and 41% (BCG-exposed/unresponsive); PFS 97% & 85%. No significant RFS difference vs BCG in comparative BCG-naïve cohorts🔗authors.elsevier.com/a/1miDg… @Pietro9609 @UroMoschini @BenjaminPradere @SBoorjian

3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26

IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU clinical trials in 2025! 1/ Practice-changing IMvigor011: In ctDNA MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%. @tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO nejm.org/doi/full/10.1056/NE…

In high-risk prostate cancer, patients staged with PSMA-PET showed longer time before biochemical relapse! @EurUrolOncol @Uroweb @APCCC_Lugano @OncoAlert @Albert0Briganti DOI: 10.1016/j.euo.2025.11.011

1/ Ze zetten in tijden van digitalisering en algoritmes hun stempel naast de stempel van het RIZIV. 2/ Ze beweren fouten bij afrekeningen te corrigeren maar zijn tegelijk de grootste ziekteverzekeraars van het land. Ze zijn stroper en boswachter tegelijk. Ze bieden allerlei diensten aan die ver buiten hun oorspronkelijke doelstellingen vallen, van verzekeringen en vakanties tot kortingsbonnen, die in een volwassen dienstenmarkt goedkoper en beter worden ingevuld. 3/ Er zijn naar schatting 1100 kantoren in België, elk met hun eigen gebouw, hiërarchie, IT-infrastructuur, koffiezetapparaat, bedrijfsauto's, maaltijdcheques, cv-ketel en poetshulp. Het "belang van hun klanten" is al opgesoupeerd voordat ze de drempel hebben overschreden.

Bladder cancer #ESMO25 in 1 slide. #goosebumps #newSOCnow #micdrop #standingovation Neoadjuvant EVP = New SOC MIBC Cis-ineligible!

Last week at #ERUS2025, @minerviniandre convinced me to give the stentless #FloRIN neobladder a go. Thanks to his tips & tricks the #neobladder part took just under 3 hours and went super smoothly. Thanks Andrea!

New EUPlatinum Opin. in European Urology: IDC & cribriform PCa = high-risk, underdetected, poorly reproducible. Time to rethink grading, imaging, and surveillance. 📄 buff.ly/OlWWTx7 #ProstateCancer #UroPath #EurUrol

Of het over corona, klimaatverandering of oorlog in het Midden-Oosten ging of gaat, geleidelijk kregen of krijgen we een narratief opgedrongen dat de ruimte voor nuance almaar verkleint en zelfs iemand met een licht afwijkende mening moreel veroordeelt. Een gevaarlijke trend.

NIAGARA’s surgical safety results #EAU25 with Jim Catto. Results show the addition of duvalumab to neoadjuvant platinum chemotherapy did not increase surgical complications or cystectomy rates.

External validation of nomograms for predicting lymph node invasion (LNI) in prostate cancer patients with negative PSMA PET-CT. What did we find? The Briganti 2023 nomogram is the most accurate! 📊✅ 🔍 Why does it matter? Extended pelvic lymph node dissection (ePLND) is the gold standard for staging but comes with risks. With PSMA PET-CT revolutionizing imaging, we need better predictive tools to avoid unnecessary procedures. 📌 Key Findings: •Among 282 patients, 13% had LNI despite negative PSMA PET-CT. •The Briganti 2023 nomogram outperformed others (C-index: 77% vs. MSKCC 64%, Briganti 2017 69%, Amsterdam-Brisbane-Sydney 64%). •Using a 5% risk cutoff would spare 47% of ePLND procedures while missing only 3.8% of LNI cases! 🚫🔬 ⚖️ Clinical Impact: •Improves decision-making: More precise risk stratification means fewer unnecessary surgeries. •Saves patients from complications: ePLND has side effects; avoiding it when possible is crucial. •Guides personalized treatment: Selecting the right patients for ePLND enhances care quality. 👨‍⚕️ Takeaway: The Briganti 2023 nomogram should be the go-to tool for predicting LNI in prostate cancer patients with negative PSMA PET-CT! 📈 🔗 Read the full study here: sciencedirect.com/science/ar… #ProstateCancer #Urology #PSMAPET #LymphNodeDissection #Nomogram

Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm acsjournals.onlinelibrary.wi…

🚨Correlates between PSMA PET and MRI for clinically significant #ProstateCancer 🚨 Our group just published in @JournalofNucMed 👉 132 tumors GG>2 from 100 pts who got both PET and MRI prior to prostatectomy @UCLAHealth 🗣️📢PET detects more tumors compared to MRI by: 1⃣Lesion (87% v 80%) & 2⃣Patient (98% v 94%) 3⃣GG2 Tumors detected by PET but not by MRI tended to be smaller on pathology 👏Ida Sonni, MD @RobertReiterMD @StevenSRaman_MD @CalaisJeremie @uclawillhsu @CzerninJohannes @UclaUrology @PCFnews @PCF_Science @AmerUrological @SUO_YUO @UroOnc